


Amendments to the Claims

1. (Original) Compound of the formula



where

R₁ is a) hydrogen, hydroxyl or amino; or

b) C₁-C₈-alkyl, C₃-C₈-cycloalkyl, C₁-C₈-alkanoyl, C₁-C₈-alkoxycarbonyl, aryl-C₀-C₄-alkyl or heterocyclyl-C₀-C₄-alkyl, which radicals may be substituted by 1-4 C₁-C₈-alkyl, halogen, oxo, cyano, trifluoromethyl, C₁-C₈-alkoxy, C₁-C₈-alkoxycarbonyl, aryl or heterocyclyl;

R₂ is a) C₁-C₈-alkyl, C₃-C₈-cycloalkyl, C₁-C₈-alkylsulphonyl, C₃-C₈-cycloalkylsulphonyl, aryl-C₀-C₈-alkylsulphonyl, heterocyclylsulphonyl, C₃-C₁₂-cycloalkyl-C₁-C₈-alkanoyl, aryl-C₁-C₈-alkanoyl, aryl-C₃-C₈-cycloalkanoyl, C₁-C₈-alkanoyl, C₁-C₈-alkoxycarbonyl, optionally N-mono- or N,N-di-C₁-C₈-alkylated carbamoyl-C₀-C₈-alkyl, aryl-C₀-C₄-alkyl or heterocyclyl-C₀-C₄-alkyl, which radicals may be substituted by 1-4 C₁-C₈-alkyl, C₃-C₈-cycloalkyl, C₃-C₈-cycloalkoxy, amino, C₁-6-alkylamino, di-C₁₋₆-alkylamino, C₁-C₆-alkanoylamino, C₁-C₈-alkoxycarbonylamino, halogen, oxo, cyano, hydroxyl, trifluoromethyl, C₁-C₈-alkoxy, C₁-C₈-alkoxycarbonyl, aryl or heterocyclyl; or

b) together with R₁ and the nitrogen atom to which they are bonded is a saturated or partly unsaturated, 4-8-membered, heterocyclic ring which may contain an additional nitrogen, oxygen or sulphur atom or an -SO- or -SO₂- group, and the additional nitrogen atom may optionally be substituted by C₁-C₈-alkyl, C₁-C₈-alkanoyl, C₁-C₈-alkoxycarbonyl, aryl or heteroaryl radicals, in which case this heterocyclic ring may be part of a bicyclic or tricyclic ring system having a total of up to 16 members and the

second ring may also contain a nitrogen, oxygen or sulphur atom or an -SO- or -SO₂- group, and the nitrogen atom of the second ring may optionally be substituted by C₁-C₈-alkyl, C₁-C₈-alkanoyl, C₁-C₈-alkoxycarbonyl, aryl or heterocyclyl radicals, and all ring systems mentioned may be substituted by 1-4 C₁-C₈-alkyl, halogen, hydroxyl, oxo, trifluoromethyl, C₁-C₈-alkoxy, C₁-C₈-alkoxy-C₁-C₈-alkyl, C₁-C₈-alkoxy-C₁-C₈-alkoxy, C₁-C₈-alkoxycarbonylamino, C₁-C₈-alkanoylamino, C₁-C₈-alkylamino, N,N-di-C₁-C₈-alkylamino, aryl-C₀-C₄-alkyl, aryloxy-C₀-C₄-alkyl, aryl-C₀-C₄-alkyl-C₁-C₈-alkoxy, aryloxy-C₀-C₄-alkyl-C₁-C₈-alkoxy, heterocyclyl-C₀-C₄-alkyl, heterocyclyloxy-C₀-C₄-alkyl, heteroaryl-C₀-C₄-alkyl-C₁-C₈-alkoxy or heterocyclyloxy-C₀-C₄-alkyl-C₁-C₈-alkoxy;

R₃ is hydrogen, C₁-C₄-alkyl, C₁-C₈-alkoxycarbonyl or C₁-C₈-alkanoyl;

R₄ is hydrogen, C₁-C₄-alkyl, C₁-C₈-alkoxycarbonyl or C₁-C₈-alkanoyl;

R₅ is in each case independently hydrogen, C₁-C₈-alkyl, or, together with the carbon atom to which they are bonded, are a C₃-C₈-cycloalkylidene radical;

R₆ is hydrogen or hydroxyl;

R, in each case independently, are 1-4 radicals selected from:

hydrogen, halogen, C₁-C₈-alkyl, 3- to 8-membered cycloalkyl, polyhalo-C₁-C₄-alkyl, C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₄-alkoxy-C₁-C₄-alkoxy-C₁-C₄-alkyl, 3- to 8-membered cycloalkoxy-C₁-C₄-alkyl, hydroxyl, C₁-C₈-alkanoyloxy-C₁-C₄-alkyl, hydroxy-C₂-C₈-alkyl, C₁-C₄-alkylthio-C₁-C₄-alkyl, C₁-C₈-alkylsulphonyl-C₁-C₄-alkyl, thiazolylthio-C₁-C₄-alkyl, thiazolinythio-C₁-C₄-alkyl, imidazolylthio-C₁-C₄-alkyl, optionally N-oxidized pyridylthio-C₁-C₄-alkyl, pyrimidinylthio-C₁-C₄-alkyl, optionally partially hydrogenated pyridyl- or N-oxidopyridyl-C₁-C₄-alkyl, C₁-C₄-alkylsulphonylamino-C₁-C₄-alkyl, trifluoro-C₁-C₈-alkylsulphonylamino-C₁-C₄-alkyl, pyrrolidino-C₁-C₄-alkyl, piperidino-C₁-C₄-alkyl, piperazino-C₁-C₄-alkyl, N'-C₁-C₄-alkylpiperazino-C₁-C₄-alkyl, N'-C₂-C₈-alkanoylpiperazino-C₁-C₄-alkyl, morpholino-C₁-C₄-alkyl, thiomorpholino-C₁-C₄-alkyl, S-oxothiomorpholino-C₁-C₄-alkyl, S,S-dioxothiomorpholino-C₁-C₄-alkyl, cyano-C₁-C₄-alkyl, carboxy-C₁-C₄-alkyl, C₁-C₄-alkoxycarbonyl-C₁-C₄-alkyl, carbamoyl-C₁-C₈-alkyl, N-mono- or N,N-di-C₁-C₄-alkylcarbamoyl-C₁-C₄-alkyl, unsubstituted or mono-, di- or tri-C₁-C₄-alkyl-, -C₁-C₄-alkoxy-, -hydroxy-, -C₁-C₄-alkylamino-, -di-C₁-C₄-alkylamino-, -halogen- or

-trifluoromethyl-substituted phenyl or naphthyl, hydroxy-C₂-C₈-alkoxy, halo-C₂-C₈-(hydroxy)alkoxy, C₁-C₈-alkylsulphonyl-C₁-C₄-(hydroxy)alkoxy, amino-C₁-C₄-alkyl, C₁-C₄-alkylamino-C₁-C₄-alkyl, N, N-di-C₁-C₄-alkylamino-C₁-C₄-alkyl, N-C₁-C₄-alkanoylamino-C₁-C₄-alkyl, C₁-C₈-alkoxycarbonylamino-C₁-C₄-alkyl, optionally partially hydrogenated pyridyl- or N-oxidopyridyl-C₁-C₄-alkyl, piperazino-C₁-C₄-alkyl, N'-C₁-C₄-alkylpiperazino-C₁-C₄-alkyl, N'-C₂-C₈-alkanoylpiperazino-C₁-C₄-alkyl, morpholino-C₁-C₄-alkyl, thiomorpholino-C₁-C₄-alkyl, S-oxothiomorpholino-C₁-C₄-alkyl, S,S-dioxothiomorpholino-C₁-C₄-alkyl, amino-C₁-C₄-alkoxy, C₁-C₄-alkylamino-C₁-C₄-alkoxy, N,N-di-C₁-C₄-alkylamino-C₁-C₄-alkoxy, C₁-C₄-alkanoylamino-C₁-C₄-alkoxy, C₁-C₈-alkoxycarbonylamino-C₁-C₄-alkoxy, C₁-C₈-alkanoyl-C₂-C₄-alkoxy which bears the alkanoyl group in a position higher than the α -position, C₁-C₈-alkoxy, 3- to 8-membered cycloalkoxy, C₂-C₈-alkenyloxy, 3- to 8-membered cycloalkoxy-C₁-C₄-alkoxy, C₁-C₈-alkoxy-C₁-C₈-alkoxy, C₁-C₄-alkoxy-C₂-C₄-alkenyl, C₂-C₈-alkenyloxy-C₁-C₄-alkoxy, C₁-C₄-alkoxy-C₂-C₄-alkenyloxy, C₂-C₈-alkenyloxy-C₁-C₄-alkyl, C₁-C₄-alkylthio-C₁-C₄-alkoxy, C₁-C₈-alkylsulphonyl-C₁-C₄-alkoxy, C₁-C₄-alkylthio-C₁-C₄-(hydroxy)alkoxy, unsubstituted or mono-, di- or tri-C₁-C₄-alkyl-, -C₁-C₄-alkoxy-, -hydroxy-, -C₁-C₄-alkylamino-, -di-C₁-C₄-alkylamino-, -halo- and/or -trifluoromethyl-substituted phenyl- or naphthyl-C₁-C₄-alkoxy, polyhalo-C₁-C₄-alkoxy, optionally partially hydrogenated pyridyl- or N-oxidopyridyl-C₁-C₄-alkoxy, thiazolyl-C₁-C₄-alkoxy, optionally N-oxidized morpholino-C₁-C₄-alkoxy, thiazolylthio-C₁-C₄-alkoxy, thiazolinythio-C₁-C₄-alkoxy, imidazolylthio-C₁-C₄-alkoxy, optionally N-oxidized pyridylthio-C₁-C₄-alkoxy, pyrimidinylthio-C₁-C₄-alkoxy, amino-C₁-C₄-alkoxy, C₁-C₄-alkylamino-C₁-C₄-alkoxy, N,N-di-C₁-C₄-alkylamino-C₁-C₄-alkoxy, C₁-C₈-alkanoylamino-C₁-C₄-alkoxy, C₁-C₈-alkylsulphonylamino-C₁-C₄-alkoxy, trifluoro-C₁-C₈-alkylsulphonyl-C₁-C₄-alkoxy, pyrrolidino-C₁-C₄-alkoxy, piperidino-C₁-C₄-alkoxy, cyano-C₁-C₄-alkoxy, carboxy-C₁-C₄-alkoxy, C₁-C₄-alkoxycarbonyl-C₁-C₄-alkoxy, carbamoyl-C₁-C₄-alkoxy, N-C₁-C₈-alkylcarbamoyl-C₁-C₄-alkoxy or N-mono- or N,N-di-C₁-C₄-alkylcarbamoyl-C₁-C₄-alkoxy, carboxy-C₁-C₄-alkyl, C₁-C₄-alkoxycarbonyl-C₁-C₄-alkyl, carbamoyl-C₁-C₈-alkyl, N-mono- or N,N-di-C₁-C₄-alkylcarbamoyl-C₁-C₄-alkyl, carboxy-C₁-C₄-alkoxy, C₁-C₄-alkoxycarbonyl-C₁-C₄-alkoxy, carbamoyl-C₁-C₈-alkoxy,

N-Mono- or N,N-di-C₁-C₄-alkylcarbamoyl-C₁-C₄-alkoxy, C₁-C₄-alkylamino or N,N-di-C₁-C₄-alkylamino,

or salt or prodrug thereof, or where one or more atoms are replaced by their stable, non-radioactive isotopes, preferably pharmaceutically usable salt thereof.

2. (Original) Compound according to Claim 1, where

R₁ is a) hydrogen; or

b) C₁-C₈-alkyl or C₃-C₈-cycloalkyl;

R₂ is a) C₁-C₈-alkyl, C₃-C₈-cycloalkyl, C₁-C₈-alkanoyl, heterocyclyl-C₁-C₈-alkanoyl, C₃-C₁₂-cycloalkyl-C₁-C₈-alkanoyl or aryl-C₁-C₈-alkanoyl, which radicals may be substituted by 1-4 C₁-C₈-alkyl, C₁₋₆-alkylamino, cyano, halogen, hydroxyl, C₁-C₆-alkanoylamino, C₁-C₈-alkoxy, oxo, trifluoromethyl or aryl; or

b) together with R₁ and the nitrogen atom to which they are bonded are a saturated or partly unsaturated, 4-8-membered, heterocyclic ring which may contain an additional nitrogen or oxygen atom, in which case the additional nitrogen atom may optionally be substituted by C₁-C₈-alkyl or C₁-C₈-alkanoyl, and this heterocyclic ring may be part of a bicyclic or tricyclic ring system having a total of up to 16 ring members and the second ring may also contain a nitrogen or oxygen atom, in which case the nitrogen atom of the second ring may optionally be substituted by C₁-C₈-alkyl or C₁-C₈-alkanoyl, and all ring systems mentioned may be substituted by 1-4 C₁-C₈-alkyl, hydroxyl, oxo, C₁-C₈-alkoxy, C₁-C₈-alkoxy-C₁-C₈-alkoxy, C₁-C₈-alkanoylamino or aryloxy-C₀-C₄-alkyl-C₁-C₈-alkoxy;

R₃ is hydrogen;

R₄ is hydrogen;


R₅ are each independently hydrogen or C₁-C₈-alkyl;

R₆ is hydrogen;

R are each independently 1-4 radicals selected from:

hydrogen, C₁-C₈-alkyl, halogen, trifluoromethyl, C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₄-alkoxy-C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₈-alkoxy, C₁-C₄-alkoxy-C₁-C₄-alkoxy, or pharmaceutically usable salt thereof.

3. (Original) Compound according to Claim 1 of the formula



where R, R₁, R₂, R₃, R₄ and R₅ are each as defined in Claim 1.

4. (Original) Compound according to Claim 1,

where R₂ together with R₁ and the nitrogen atom to which they are bonded is a substituted or unsubstituted heterocyclic ring selected from pyrrolidino, piperidino, pyridinyl, piperazino, morpholino, thiomorpholino, furanyl, tetrahydrofuranyl, pyranyl, tetrahydropyranyl, thiazolyl, oxazolyl, imidazolyl, indolinyl, isoindolinyl, 2,3-dihydrobenzimidazolyl, 1,2,3,4-tetrahydroquinolyl, 1,2,3,4-tetrahydroisoquinolyl, 1,2,3,4-tetrahydro-1,3-benzodiazinyl, 1,2,3,4-tetrahydro-1,4-benzodiazinyl, 3,4-dihydro-2H-1,4-benzoxazinyl, 3,4-dihydro-2H-1,4-benzothiazinyl, 3,4-dihydro-2H-1,3-benzothiazinyl, 3,4,5,6,7,8-hexahydro-2H-1,4-benzoxazinyl, 3,4,5,6,7,8-hexahydro-2H-1,4-benzothiazinyl, 9-azabicyclo[3.3.1]non-9-yl, 1-azepan-1-yl, 2,8-diazaspiro[4.5]dec-8-yl, octahydroisoindol-2-yl, 4-azatricyclo[5.2.1.0^{2,6}]dec-4-yl, 3-azabicyclo[3.2.1]oct-3-yl, 3,7-diazabicyclo[3.3.1]non-3-yl, 3-azabicyclo[3.3.1]non-3-yl, 8-azabicyclo[3.2.1]oct-8-yl, 3-azabicyclo[3.2.2]non-3-yl, 2,3,4,5-tetrahydro-1H-1-benz[6,7-b]azepinyl and 5,6-dihydrophenanthridinyl.

5. (Currently amended) Compound according to ~~one of Claims 1-4~~ Claim 1 for use in a method for therapeutically treating the human or animal body.

6. (Currently amended) Pharmaceutical preparation comprising, as an active pharmaceutical ingredient, a compound according to ~~one of Claims 1-4~~ Claim 1 in free form or as a pharmaceutically usable salt.

7. (Currently amended) Use of a compound according to ~~one of Claims 1—4~~ Claim 1 for the preparation of a pharmaceutical preparation with renin-inhibiting action.
8. (Currently amended) Use of a compound according to ~~one of Claims 1—4~~ Claim 1 for the preparation of a pharmaceutical preparation for the treatment or prevention of hypertension, heart failure, glaucoma, cardiac infarction, kidney failure or restenosis.
9. (New) Pharmaceutical preparation comprising, as an active pharmaceutical ingredient, a compound according to Claim 2 in free form or as a pharmaceutically usable salt.
10. (New) Pharmaceutical preparation comprising, as an active pharmaceutical ingredient, a compound according to Claim 3 in free form or as a pharmaceutically usable salt.
11. (New) Pharmaceutical preparation comprising, as an active pharmaceutical ingredient, a compound according to Claim 4 in free form or as a pharmaceutically usable salt.